The effect on HbA1c in patients with diabetes mellitus when receiving either intravenous or erythropoietin stimulating agent therapy: a prospective follow-up study

Hull and East Yorkshire Hospitals NHS Trust (UK)0 个研究点目标入组 30 人开始时间: 2010年5月12日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Patients with established chronic kidney disease (stage III - IV) (estimated glomerular filtration rate [eGFR] using Modification of Diet in Renal Disease [MDRD] 15 - 59 mL/min/1.73 m^2) who are to undergo iron and/or erythropoiesis stimulating agent (ESA) therapy
•2. Patients who have established diabetes mellitus - both type I and II
•3. Patients with no prior diagnosis of diabetes mellitus (control group)
•4. Aged 18 to 80 years, either sex

•1. Patients who not have renal failure (CKD stage I and II)
•2. Patients who are unable or do not wish to give consent
•3. Patients with currently investigated for potential blood loss
•4. Patients with a haematological malignancy/haemolysis
•5. Patients with known haemaglobinopathy
•6. Patient with significant liver disease (prothrombin time [PT] greater than 16)
•7. Patients with a diagnosis of myeloma
•8. Patients with severe hyperparathyroidism (parathyroid hormone [PTH] greater than 800 picograms/ml)

发起方

Hull and East Yorkshire Hospitals NHS Trust (UK)